On November 9, a delegation from the National Security Commission on Emerging Biotechnology arrived at Stony Brook University’s campus to explore research that could influence health care, industry and national defense. More than fifty attendees (ranging from faculty and graduate students to representatives of U.S. Representatives Laura Gillen, Andrew Garbarino and Nick LaLota) gathered in the Hilton Garden Inn ballroom for a day of demonstrations, panels and informal networking.
Cutting-edge projects presented by Stony Brook researchers
One of the headline demonstrations came from biomedical engineer Hassan Arbab. His team applies spectroscopy to burned tissue, generating a spectral fingerprint that predicts whether the wound will heal without intervention. Pre-clinical and early clinical trials reported an accuracy of 90-95 %, far above the 50-70 % reliability of visual assessments. The method promises to reduce unnecessary graft surgeries, especially in mass-casualty scenarios where rapid triage is essential.
In the realm of drug discovery, Martin Akerman, co-founder of Envisagenics, explained how his company leverages artificial intelligence to interrogate RNA splicing patterns. By identifying novel splice variants, the platform pinpoints targets for oncology and other disease areas. A recent collaboration with Boehringer Ingelheim could generate more than $1 billion in milestones if the partnership reaches its development goals.
RNA-based therapeutics also featured prominently. Anton Xavier, CEO of iNanoRNA Therapeutics, traced his company’s journey from a Stony Brook spin-out to Phase 1 clinical testing, emphasizing early support from the NIH-funded REACH program. Similarly, Joseph Scaduto presented two drug candidates originally derived from skin-condition research that now address chemical, biological, radiological and nuclear threats, illustrating the dual-use nature of biotech innovations.
Industry voices and policy implications
Adam Volini of Empire State Development raised a strategic question: when cost-driven decisions push manufacturers abroad, does the United States sacrifice its national security? He warned that the “right business decision can become the wrong national-security decision,” urging policymakers to align economic incentives with domestic production.
The commission’s executive director, Caitlin Frazer, reminded the audience that biotechnology extends beyond medicines. Advances in bio-manufacturing influence material synthesis, renewable fuels and critical-mineral extraction, sectors where China currently holds a competitive edge. Frazer cited the bipartisan commission’s April 2025 report (49 recommendations, more than 80 % already moving forward) to illustrate the federal momentum toward a resilient biotech ecosystem.
Stony Brook’s own Center for Biotechnology celebrated a four-decade track record of translating discoveries into FDA-approved products. William Wertheim, executive vice president for Stony Brook Medicine, noted that the center has helped bring over a dozen therapeutics to market, underscoring the university’s role as an innovation hub.
Academic perspectives and the call for curiosity-driven research
During a panel moderated by John Prufeta, founder of Medical Excellence Capital, entrepreneurs discussed the steep costs of clinical translation, regulatory hurdles and the necessity of patient-stage investors. Andrew Singer, dean of the College of Engineering and Applied Sciences, highlighted the legacy of magnetic resonance imaging pioneer Paul Lauterbur and linked it to current work in quantum computing and AI for drug design.
Ken Dill, Laufer Family Endowed Professor, urged the commission to recognize research that lies “upstream of the upstream.” He suggested adding a 50th recommendation that explicitly protects curiosity-driven inquiry, whose eventual applications cannot always be predicted.
The day concluded with a session at the Alan Alda Center for Communicating Science, where participants practiced non-verbal mirroring exercises to improve public engagement. Frazer emphasized that improving bioliteracy is akin to basic computer literacy: citizens do not need to program, but they should understand the technology that affects their lives.
University President Andrea Goldsmith presented the commission with Stony Brook pins and articulated a vision of turning Long Island into “Silicon Island.” She highlighted graduate students and postdoctoral scholars as the next wave of entrepreneurs, and called on Washington to maintain robust federal research funding that embraces high-risk, high-reward projects.



